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Abstract
Comparative chemotherapy-related quality of life data are lacking. Bendamustine-rituximab (BR) demon-
strated noninferiority to R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)/R-CVP
(rituximab/cyclophosphamide/vincristine/prednisone) in ﬁrst-line advanced indolent non-Hodgkin and mantle
cell lymphomas. Patients receiving BR reported improvement across many domains, with a few exceptions, of
the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.
Background: We previously reported results of the phase III, randomized, noninferiority trial comparing
bendamustine-rituximab (BR) with standard R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/predni-
sone)/R-CVP (rituximab/cyclophosphamide/vincristine/prednisone) in previously untreated advanced indolent
non-Hodgkin and mantle cell lymphomas. Here we report health-related quality of life (HRQOL) results from the
trial. Methods: HRQOL, as measured by the European Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire Core 30 (EORTC QLQ-C30), was a secondary end point. Differences between group means in
global health status (GHS), 5-item functioning, and 9 symptoms/single-item measures at week 1 of cycle 1 and end-of-
cycles 3 and 6 were examined using the screening (baseline) score as a covariate in analysis of covariance. Results:
Overall EORTC QLQ-C30 compliance was 75.2%, 89.5%, and 89.9% at week 1 of cycle 1 and end-of-cycles 3 and 6,Presented in part as an oral presentation at the 54th Annual Meeting of the American
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respectively. Patients treated with BR reported improvements in Cognitive Functioning, Physical Functioning, Social
Functioning, Emotional Functioning, and GHS as well as reduction in dyspnea, constipation, and fatigue at some, but
not all, time points. Patients treated with standard therapy reported less nausea/vomiting at one time point.
Conclusion: Compared with patients treated with standard therapy, patients treated with BR reported better quality of
life in several areas.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 16, No. 4, 182-90 ª 2016 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The impact of cancer treatment on health-related quality of life
(HRQOL) has been increasingly considered in regulatory and
clinical decision-making. Studies have found higher psychological
distress associated with low functioning scores on HRQOL in-
struments, and these effects can be seen years after completion of
cancer therapy.1,2
Patient-reported outcomes (PROs) can provide a valuable perspec-
tive on treatment tolerability.3,4 In addition to the disease-associated
symptoms patients experience, chemotherapy treatment of non-
Hodgkin lymphoma (NHL) can be physically and emotionally
taxing, as shown by 3 PRO assessments in a study of 222 follicular
lymphoma patients, as well as by 3 quality of life (QOL) questionnaires
in a study of 132 elderly patients with aggressive NHL.5,6 The clinical
importance of HRQOL in evaluating the tolerability effects of various
treatment regimens in advanced cancer was highlighted by the recent
publication of PRO results of patients with advanced cervical cancer
and poor prognosis in a “practice-changing” phase 3 study, in which
improvements in both overall survival and progression-free survival
(PFS) related to the addition of a new agent to chemotherapy were not
accompanied by a decline in HRQOL.7 Despite the importance of
HRQOL during cancer treatment, there are few data comparing
treatment regimens for impact on HRQOL in NHL.
Our recent randomized, open-label, phase III, global trial
demonstrated noninferiority of complete response rate (primary
objective) between bendamustine-rituximab (BR) and standard
rituximab-based chemotherapy (rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone [R-CHOP] or rituximab,
cyclophosphamide, vincristine, and prednisone [R-CVP]) in ﬁrst-line
treatment of patients with indolent NHL or mantle cell lymphoma
(MCL) (31%vs. 25%, respectively; P¼ .0225 for noninferiority).8 In
the open-label, randomized, multicenter, phase III, noninferiority
Study group indolent Lymphomas (StiL) trial, PFS was signiﬁcantly
longer for BR therapy versus standard R-CHOP in treatment-naive
patients with MCL or indolent NHL (at median follow-up of 45
months, median PFS was 69.5 vs. 31.2 months, respectively; P <
.0001 for superiority).9
At present, all 3 treatment regimens (BR, R-CHOP, and R-CVP)
are recommended ﬁrst-line treatments for follicular lymphoma.10
HRQOL data for these regimens could help physicians choose
the best treatment regimen. In a recent cost-utility analysis using
EQ-5D utility scores from a follicular lymphoma study, the clinical
beneﬁts of BR observed in the StiL study and in a patient-simulated
model translated into 7.19 total quality-adjusted life-years (QALYs)versus 6.46 for R-CHOP and 6.58 for R-CVP, a gain of 0.73 and
0.61 QALYs, respectively.9,11,12
In this report, we analyzed HRQOL data, as assessed by the
European Organisation for Research and Treatment of Cancer
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30),
collected during the Bendamustine Rituximab InvestiGational
non-Hodgkin’s Trial (BRIGHT).8
Patients and Methods
The study design, enrollment eligibility, exclusion criteria,
treatment plan, and efﬁcacy/safety results of the BRIGHT trial have
been reported in detail elsewhere.8 To summarize, the BRIGHT
trial was a randomized, multicenter, open-label, active-controlled,
phase III study that was conducted to compare the efﬁcacy and
safety of intravenous combination therapy of bendamustine (90
mg/m2/day on days 1 and 2) and rituximab (375 mg/m2 on day 1)
in 28-day cycles with that of R-CHOP/R-CVP for six 21-day cycles
in the treatment of treatment-naive patients with advanced, CD20-
positive indolent NHL or MCL. Patients were preassigned by in-
vestigators to a standard treatment (R-CHOP or R-CVP) at
screening; patients were then randomly assigned to a standard
treatment or BR for 6 cycles (up to 8 cycles at investigator
discretion).8 Eligibility criteria included an Eastern Cooperative
Oncology Group (ECOG) performance status of  2; estimated
life expectancy of  6 months; and adequate renal, hepatic, and
hematologic function. The primary end point was the proportion of
patients with complete response at the end of treatment.8 Among
the secondary outcome measures were QOL and the incidence of
adverse events (AEs) throughout treatment.8 The study protocol
was approved by institutional review boards at all institutions that
participated. Written informed consent was provided by all patients
who enrolled in this trial.8 The BRIGHT study is registered with
ClinicalTrials.gov (identiﬁer: NCT00877006).
Procedures for HRQOL and Safety Data Collection
The EORTC QLQ-C30 is a standardized tool that incorporates a
global health status (GHS)/QOL scale, 5 functional scales (physical,
role, emotional, cognitive, and social), 3 symptom scales (fatigue,
nausea/vomiting, and pain), and 6 single-item measures (dyspnea,
insomnia, appetite loss, constipation, diarrhea, and ﬁnancial
impact); all scores could range from 0 to 100, with rising scores on
functional and GHS/QOL scales indicating improvement and rising
scores on symptom/single-item scales indicating worsening.13 Pa-
tients completed the EORTC QLQ-C30 form at baseline, week 1Clinical Lymphoma, Myeloma & Leukemia April 2016 - 183
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184 -of cycle 1, and at the end of cycles 3, 6, and 8 (if applicable). Pa-
tients who did not complete treatment at cycle 3, 6, or 8, or as per
the protocol, received an end-of-treatment assessment. The
magnitude of observed differences between the BR and R-CHOP/
R-CVP groups was analyzed according to EORTC QLQ-C30
guidelines.14
All AEs reported with onset at or after the ﬁrst dose in both
treatment groups were summarized by worst severity according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0, per patient using the
Medical Dictionary for Regulatory Activities preferred term.
Incidence rates were calculated by treatment and preferred
term.
Statistical Analysis
Study sample size was established to power analysis of the pri-
mary efﬁcacy end point. The hypothesis of interest for the
HRQOL analysis was superiority of BR over the standard treat-
ments. Subgroup analyses by predetermined standard regimen (R-
CVP or R-CHOP) were preplanned. Univariate statistics and
simple hypothesis tests compared means between treatment groups.
The differences between group means were tested using t-tests
under the assumption of equal variances. All hypothesis tests were
conducted at the a level of 0.05, and no corrections were made for
multiple comparisons. Differences between group means were
examined using the screening (baseline) score as a covariate in the
linear model on the basis of an analysis of covariance. For all var-
iables, only the observed data from the patients were used in the
statistical analyses.
The assumption of parallel slopes was tested, post hoc, by ﬁrst
ﬁtting a model that included a term for the interaction between the
treatment indicator variable and the baseline covariate. A statistically
signiﬁcant interaction parameter estimate served as evidence for
violation of the parallel slopes assumption that the treatment effect
is consistent across the entire range of baseline scores. The presence
of such an interaction precludes the interpretation of the simpler
model that includes only main effects. Under such circumstances, a
Johnson-Neyman analysis was used to identify regions of signiﬁ-
cance. For example, a difference between the groups in the fre-
quency of an AE effect might exist only across a limited range of
baseline scores. Or, in one range of baseline scores, one treatment
arm could be superior, whereas in another range of baseline scores,
the other arm could be superior.15
Results
Patients
From April 27, 2009, to March 31, 2012, 447 patients were
enrolled (Figure 1). A total of 209 patients were preassigned to
R-CHOP (105 patients randomized to BR and 104 to R-CHOP)
and 238 to R-CVP (119 patients each randomized to BR and
R-CVP).
Overall, the patient demographic and clinical characteristics at
baseline were similar across treatment arms (Table 1).8 The median
age at baseline for patients treated with BR or a standard therapy
was 60 years (range, 28 to 84 years) and 58 years (range, 25 to 86
years), respectively. The majority of patients were male (61% and
59% for BR and standard therapy, respectively) and white (92%Clinical Lymphoma, Myeloma & Leukemia April 2016and 89%, respectively), and had indolent NHL (83% each), an
ECOG status of 0 (64% each), and Ann Arbor stage IV lymphoma
(69% and 68%, respectively) with no B symptoms (61% and 57%,
respectively). Of the patients preassigned to R-CVP (regardless of
whether they were randomized to BR or standard therapy), 61%
had an ECOG score of 0; of the patients preassigned to R-CHOP,
68% had an ECOG score of 0.
HRQOL Results
Compliance with the EORTC QLQ-C30 tool was high
(75%) at all time points during treatment, though this was not
true for the 19 patients who came off study early and therefore,
per the protocol, were to complete an end-of-treatment visit
including the QOL assessment form (Table 2). The proportion of
patients who completed the forms in each treatment group was
similar.
Treatment with BR was associated with improved functioning
scores at several time points. Speciﬁcally, scores for Cognitive
Functioning, Physical Functioning, Social Functioning, and
Emotional Functioning at various time points were either the same
or improved with BR compared with standard therapy (Figure 2).
For example, as shown in Figure 2, patients in the BR group re-
ported improved Cognitive Functioning compared with patients
treated with standard therapy at the end of cycles 1 and 3; though
the difference at the end of cycle 6 was not statistically signiﬁcant,
the trend was the same. Similarly, patients treated with BR re-
ported improved Physical Functioning throughout therapy; how-
ever, statistical signiﬁcance was reached only at the end of cycle 6.
There was no statistically signiﬁcant difference in Role Func-
tioning between the two groups at any time point while the trend
was in favor of BR. Patients treated with BR reported improved
GHS compared with patients treated with standard therapy, but
the improvement reached statistical signiﬁcance only at the end of
cycles 3 and 6.
Treatment with BR was also associated with improvements in
several of the symptoms addressed by the QOL tool (Figure 2,
Figure 3). Speciﬁcally, patients in the BR group reported less con-
stipation, dyspnea, and fatigue compared with patients treated with
standard therapy at  1 time point. No signiﬁcant differences were
found between the groups in the degree of appetite loss, diarrhea,
ﬁnancial difﬁculties, insomnia, and pain. The only symptom that
improved with standard therapy was nausea and vomiting at the end
of cycle 3 in patients who started with lower level scores at baseline;
however, the small number of patients in the Johnson-Neyman
analysis portion of the graph raises the question of the reproduc-
ibility of this result.
In a preplanned subanalysis, QOL scores were compared within
each preassigned standard treatment group between randomized
subgroups (eg, among patients preassigned to R-CHOP, the com-
parison was between BR and R-CHOP; Table 3). Among patients
preassigned R-CHOP, scores for GHS, Cognitive Functioning,
diarrhea, fatigue, and pain were signiﬁcantly better in patients
randomized to BR treatment than to R-CHOP at 1 or 2 time
points; however, in patients who had a low baseline level of nausea
and vomiting, nausea and vomiting were decreased at the end of
cycle 3 in patients randomized to R-CHOP as compared with those
randomized to BR. It should be noted that a higher percentage of
Figure 1 CONSORT Diagram of Patient Disposition. *Efﬁcacy-Evaluable Treated Patients who Have a Baseline and at Least One Post-
Baseline Efﬁcacy Evaluation, or who Discontinued Due to Progressive Disease and Did Not Have Major Protocol Violations.
Republished With Permission From the American Society of Hematology, From Flinn IW, et al. Randomized Trial of
Bendamustine-Rituximab or R-CHOP/R-CVP in First-Line Treatment of Indolent NHL or MCL: the BRIGHT Study. Blood 2014;
123; Permission Conveyed Through Copyright Clearance Center, Inc
Abbreviations: AE ¼ Adverse event; BR ¼ bendamustine and rituximab; PD ¼ progressive disease; R-CHOP ¼ rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP ¼
rituximab, cyclophosphamide, vincristine, and prednisone.
John M. Burke et althe R-CHOP group (23%) versus the other treatment groups (9%
for BR, 3% R-CVP) received aprepitant.8 Among patients preas-
signed to R-CVP, scores for GHS, appetite loss, constipation,
diarrhea, dyspnea, and all the functions were signiﬁcantly better in
patients randomized to BR than to R-CVP at 1 or 2 time points;
however, diarrhea was decreased at the end of cycle 3 in patients
randomized to R-CVP compared with those randomized to BR.
Overall, BR led to more QOL improvements when compared with
R-CVP than it did when compared with R-CHOP.
Discussion
A key secondary objective of the randomized BRIGHT trial was
the assessment of QOL during treatment with BR and standard R-
CHOP/R-CVP. As early as 1 week into the study, we observed
signiﬁcant QOL differences between the BR and the standard R-
CHOP/R-CVP groups. In all, there were 7 domains for which
there was a signiﬁcant improvement with the BR regimen at one
time point or more; these domains were Cognitive Functioning,
Physical Functioning, Social Functioning, Emotional Functioning,
constipation, dyspnea, and fatigue. On the other hand, there was
only one domain—nausea and vomiting—for which there was an
improvement with standard R-CHOP/R-CVP therapy.
The magnitude of the differences in QOL observed tended to be
small, according to EORTC QLQ-C30 interpretation guidelines.14For example, the mean difference in GHS between the BR and
standard therapy groups was 6.4 by the end of cycle 6, which is
considered a small improvement in GHS. Likewise, the clinical
signiﬁcance of the other statistically signiﬁcant differences observed
between the groups was small or insigniﬁcant.
The differences in QOL scores between the two treatment groups
tended to be fairly consistent at the different time points measured,
though the statistical signiﬁcance of the differences varied.
By preassigned treatment group, BR therapy led to a greater
improvement in QOL compared with R-CVP than it did compared
with R-CHOP. While this may seem counterintuitive, it can
probably be explained by the fact that some physicians, depending
on the region and medical practice, almost certainly assigned more
frail patients to receive R-CVP over R-CHOP. The more frail pa-
tients were likely to experience more toxicity, which would make R-
CVP appear to be more toxic than R-CHOP. The fact that 61% of
R-CVP patients had a baseline performance status of 0, whereas
68% of R-CHOP patients had a baseline performance status of 0,
supports this hypothesis.
The frequency of AEs as previously reported8 and documented by
physicians at ofﬁce visits did not always parallel the same symptoms
as documented by the patient-reported EORTC QLQ-C30. For
example, fatigue as measured by the EORTC QLQ-C30 was
signiﬁcantly improved at several time points in the BR groupClinical Lymphoma, Myeloma & Leukemia April 2016 - 185
Table 1 Demographic and Baseline Characteristics (Ran-
domized Population)
Characteristic
BR (n [ 224)
R-CHOP/R-CVP
(n [ 223)
Patients Patients
No. % No. %
Age, years
Median 60 58
Range 28-84 25-86
Male 136 61 132 59
Eastern Cooperative Oncology
Group performance status
0 144 64 143 64
1 70 31 69 31
2 10 4 10 4
Histology at diagnosis
Follicular, grade 1 or 2 154 69 160 72
Marginal zone 28 12 18 8
Mantle cell 36 16 38 17
Lymphoplasmacytic 5 2 6 3
Missing 1 <1 1 <1
Ann Arbor stage
I 1 <1 1 <1
II 21 9 21 9
III 48 21 49 22
IV 154 69 152 68
B symptoms
Present 81 36 88 39
Absent 136 61 127 57
Unknown 7 3 8 4
Mean pretreatment EORTC
QLQ-C30 scoresa
Functioning
Cognitive 83.4 83.9
Physical 86.2 85.5
Role 79.2 78.7
Social 79.2 83.7
Emotional 76.9 76.1
Symptoms
Appetite loss 18.6 17.1
Constipation 10.6 13.5
Diarrhea 11.5 9.8
Dyspnea 15.6 17.5
Fatigue 28.9 29.8
Financial difﬁculties 19.7 20.4
Insomnia 26.7 32.1
Nausea/vomiting 6.1 6.3
Pain 20.4 21.7
Abbreviations: BR ¼ bendamustine and rituximab; EORTC QLQ-C30 ¼ European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; R-CHOP ¼ rit-
uximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP ¼ rituximab,
cyclophosphamide, vincristine, and prednisone.
an ¼ 208 for each treatment group.
Table 2 Patient Compliance With Completing the EORTC
QLQ-C30 Form
Assessment
Time
BR
Completed
Forms/Total
Patients
No./No.
R-CHOP/R-CVP
Completed
Forms/Total
Patients
No./No.
Safety
Population
Total
Compliance
Rate %
Baseline 205/221 202/214 93.6
Cycle 1 week 1 159/221 168/214 75.2
End of cycle 3 192/215 184/205 89.5
End of cycle 6 180/203 178/195 89.9
End of cycle 8 40/45 64/71 89.7
End of treatment 10/19 11/19 55.3
Abbreviations: BR ¼ bendamustine and rituximab; EORTC QLQ-C30 ¼ European Organisation
for Research and Treatment of Cancer Quality of Life Questionnaire C30; R-CHOP ¼ rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP ¼ rituximab, cyclophos-
phamide, vincristine, and prednisone.
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reporting, the rate of fatigue between the two groups was similar.
Conversely, according to physician AE reporting, constipation
occurred less frequently in the BR group, whereas, according to the
EORTC QLQ-C30, constipation was less with BR but only at one
point in time. We can only speculate as to the reasons for the dif-
ferences in results obtained by physician AE reporting and patient
reports on the EORTC QLQ-C30. Possible explanations include
the inherent potential limitation of physician AE reporting of not
gathering information on every possible side effect (eg, patients may
not report symptoms that they perceive to be minor or transient,
such as constipation for a few days, to the physicians) and the po-
tential for minor AEs not having a signiﬁcant impact on QOL.16
The fact that physician-reported AEs differed somewhat from
patient-reported QOL suggests that both may be important for
understanding the impact of different treatments on patients. The
current tendency to focus only on physician-reported AEs when
evaluating new therapies may lead to a lack of true understanding of
the AEs of those therapies and their impact on patients’ QOL.
One limitation of this study was the use of the EORTC QLQ-C30
alone for the assessment of HRQOL. Although the EORTC QLQ-
C30 is widely used in clinical trials, the instrument has not been
incorporated into clinical practice.14 This tool does not provide a
comprehensive review of HRQOL.17 For example, there are no
questions regarding sexual functioning, in contrast to other QOL in-
struments, although many patients may not initiate this discussion with
their physician unprompted.18 Supplementation of this tool with
another instrument that includes additional aspects of HRQOL may
have provided a more comprehensive reporting of patient HRQOL.
Another limitation is that QOL was assessed only during treat-
ment. Long-term HRQOL, including physical aspects, has been
shown to be reduced among survivors of NHL.1,19 The extent to
which long-term HRQOL is related to therapy itself is not clear. As
expected, the BR group in the BRIGHT study had a signiﬁcantly
lower incidence of peripheral neuropathy (4% vs. 21% for R-
CHOP and 26% for R-CVP)8; however, as discussed above, AEs do
not directly translate into reduced HRQOL.
Figure 2 EORTC QLQ-C30 Domain Scores Forest Plot Comparing BR With R-CHOP/R-CVP (Difference). Horizontal Bars Represent
Standard Error;  Shows Statistical Signiﬁcance, P < .05 ANCOVA; x Shows Statistical Signiﬁcance Over a Portion of the
Range (Outside of the Listed Bounds), by Johnson-Neyman Analysis
Abbreviations: ANCOVA ¼ Analysis of covariance; BR ¼ bendamustine-rituximab; JN ¼ Johnson-Neyman analysis; JNþ ¼ bendamustine-rituximab superior in a portion of the range;
JN ¼ bendamustine-rituximab superior for a portion of the range, while the comparator treatments superior for another portion of the range.
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Figure 3 Johnson-Neyman Analysis of Fatigue. The Best Fit Lines in the End of Cycle 3 and End of Cycle 6 Plots Are Separated and
Parallel, Indicating that Fatigue Was Less With BR (Solid Line) Compared With Standard Therapy (Dashed Line) at These
Time Points. However, the Best Fit Lines in the End of Cycle 1 Plot Were Not Parallel. In This Situation, a Johnson-Neyman
Analysis Was Used. The Shaded Area Below a Score of 48.8 Indicates that, in Patients With Low Levels of Fatigue at
Baseline, There Was No Statistically Signiﬁcant Difference Between the Groups in Level of Fatigue at the End of Cycle 1; in
Contrast, in Patients With Higher Levels of Fatigue at Baseline, Treatment With BR Resulted in a Lower Level of Fatigue
Compared With Standard Therapy at the End of Cycle 1
Abbreviations: BR ¼ bendamustine-rituximab; CI ¼ conﬁdence interval.
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188 -Finally, the lack of blinding of the treatment arms may have
inﬂuenced the QOL results in this global study. Patients’ reporting
of the results may have been inﬂuenced by pre-existing overall biases
about expected toxicities.
Conclusion
The clinical efﬁcacy of the BR regimen has been demonstrated in
several clinical trials.8,9 In this analysis, the impact of BR treatment on
QOL was compared with other standard therapies for indolent NHL
and MCL. In general, patients receiving BR reported greater
improvement across select QOL domains compared with patients
receiving standard therapy, though the clinical signiﬁcance of the
beneﬁts was small, and the differences between the groups were not
statistically signiﬁcant at all points in time. We have observed in
clinical practice a recent trend toward the use of BR over R-CHOP or
R-CVP, presumably because BR causes less risk of alopecia, cardiac
toxicity, and peripheral neuropathy and has shown to improvemedian
PFS in one study.9,10 While caution should be exercised when
interpreting the results, the QOL data that we present in this paper
provide additional justiﬁcation for the observed trend.Clinical Practice Points
 Despite the importance ofHRQOLduring cancer treatment, therapy-
regimen comparison data for impact on HRQOL are lacking.Clinical Lymphoma, Myeloma & Leukemia April 2016 BR, R-CHOP, and R-CVP are currently recommended as ﬁrst-
line treatments for follicular lymphoma, and HRQOL data for
these regimens could help physicians choose among them.
 As measured by the EORTC QLQ-C30, our analysis of the
impact of BR treatment on QOL, compared with other standard
therapy for advanced indolent NHL and MCL, found that pa-
tients receiving BR reported greater improvement across select
QOL domains.
 Clinical signiﬁcance of QOL beneﬁts in patients receiving BR
regimen was small, and the differences between the groups were
not statistically signiﬁcant at all points in time.
 These results provide additional support for the potential of
ﬁrst-line use of BR in patients with advanced indolent NHL or
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Social functioning .1232 .0739 .2646 JND .5223 JND
Emotional functioning .4141 .1208 .5357 JND .2235 JND
Symptoms or single items
Appetite loss .5630 .5265 .9594 JND .3420 .1742
Constipation .1241 .1096 .4206 JND .0215 .2878
Diarrhea JND .4390 JND .5657 JNL .0422
Dyspnea .3983 .1719 .4411 .1600 .0439 .1688
Fatigue .1826 .1998 .0441 .8786 .1113 .0612
Financial difﬁculties .1707 .3650 .4119 .6557 .8138 .6781
Insomnia .8355 .2142 .9556 .2828 .9767 .0668
Nausea/vomiting .8839 JNL .5499 .0656 .4107 .6916
Pain .0351 .2874 .2998 .1968 .6356 .1294
Abbreviations: BR ¼ bendamustine and rituximab; EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; JNþ ¼ bendamustine-
rituximab superior; JN ¼ comparator treatments superior; JN ¼ Johnson-Neyman analysis; R-CHOP ¼ rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP ¼ ritux-
imab, cyclophosphamide, vincristine, and prednisone.
aNo adjustments were made for multiple comparisons; bold-faced P values indicate a statistical signiﬁcant improvement for the BR group.
bAt baseline, 103 patients received BR and 98 patients received R-CHOP.
cAt baseline, 118 patients received BR and 116 patients received R-CVP.
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